An annual low-dose CT scan is recommended, per the US Preventive Services Task Force's 2021 recommendation, for adults aged 50 to 80 who have a 20 pack-year smoking history, who currently smoke or quit within the past 15 years, and who would be healthy enough for treatment if cancer were found. The case rests on hard numbers: in the National Lung Screening Trial, cited by the National Cancer Institute, annual low-dose CT reduced lung cancer deaths by 20 percent compared with chest X-ray, and lung cancer remains the leading cause of cancer death in the United States, with an estimated 226,650 new cases projected for 2025 by NCI.
This article explains the qualifying criteria, the evidence behind the scan, the risks of screening, and how the process works. Newspaper Daily publishes information, not medical advice; eligibility in an individual case should be confirmed with a clinician.
Who meets the screening criteria?
The USPSTF's 2021 recommendation, the standard most US insurers follow, defines eligibility with three measurements. The first is age: 50 through 80. The second is smoking exposure, counted in pack-years, meaning the average packs per day multiplied by years smoked; 20 pack-years could be a pack a day for 20 years, two packs a day for 10 years, or any equivalent combination. The third is smoking status at the time of screening: currently smoking, or having quit within the last 15 years.
The criteria stop screening at age 80 or after 15 years of quitting, whichever comes first. These cutoffs reflect where trial evidence showed benefit exceeding harm, not a judgment about the cancer risk itself, which stays elevated for life. The 2021 criteria broadened an earlier version from 2013, which had started at age 55 and required 30 pack-years; the American Lung Association estimated in reports following the change that roughly 14 million additional Americans became eligible.
How strong is the evidence that screening saves lives?
Two trials anchor the field. The National Lung Screening Trial, sponsored by the National Cancer Institute and reported in 2011, randomized more than 53,000 current or former heavy smokers to annual low-dose CT or annual chest X-ray for three rounds, and found a 20 percent relative reduction in lung cancer deaths. The Dutch-Belgian NELSON trial, published in the New England Journal of Medicine in 2020, found a 24 percent reduction among men screened with low-dose CT versus no screening, with an even larger 33 percent reduction in women.
Two structural facts make lung screening different from many cancer screenings. First, only low-dose CT qualifies: chest X-rays do not detect early tumors reliably enough, and no blood test or breath test currently substitutes. Second, the benefit depends on the follow-through: if a scan finds a nodule requiring imaging surveillance or treatment, the survival advantage applies mainly to people healthy enough and willing to undergo that workup, which is why the USPSTF criteria include fitness for treatment.
What does a low-dose CT scan involve?
The scan itself takes under 10 minutes. The machine rotates around the chest, capturing a three-dimensional image with roughly one-seventh the radiation of a standard chest CT, per NCI materials. No contrast dye is injected, no fasting is required, and the person lies still on a table that slides through an open ring. Results are reported using a standardized grading scale called Lung-RADS, developed by the American College of Radiology, which sorts findings into categories that determine next steps.
Related stories: The HPV Vaccine for Adults: What to Know About Age Limits and Catch-Up Dosing · Sunscreen and Skin Cancer Prevention: What the Evidence Supports.
What happens if a nodule is found?
Nodules are the norm rather than the exception: a large share of screened smokers have at least one small lung nodule, and the overwhelming majority turn out to be old scar tissue, inflammation, or benign growths. Under Lung-RADS, small nodules typically lead to a repeat scan in three to 12 months, larger or faster-growing nodules lead to PET imaging or biopsy, and clearly suspicious findings lead to treatment. False positives, in the sense of nodules that look concerning and later prove benign, are common, but CDC materials note that most are resolved with imaging alone rather than invasive procedures.
What are the risks and limits of screening?
Honest accounting includes several. False positives generate anxiety and sometimes invasive biopsies, though the Lung-RADS system was designed to reduce that burden. Radiation from repeated annual scans carries a theoretical cancer risk, which the National Cancer Institute describes as small relative to the screening benefit in eligible people. Overdiagnosis, finding slow-growing tumors that would never have caused symptoms, occurs in a minority of detected cancers, with NCI-cited estimates in the low double digits as a percentage of screen-detected cases. And critically, screening detects cancer, it does not prevent it; quitting smoking remains the intervention with by far the largest effect on lung cancer risk, a point both the USPSTF and CDC emphasize alongside their screening statements. Insurers including Medicare cover the annual scan for eligible people under the USPSTF criteria, typically with a shared decision-making visit first.
What does getting screened actually look like?
Operationally, the process starts with a conversation rather than an order. CDC materials describe a shared decision-making visit, during which a clinician confirms the pack-year count, discusses the balance of benefits and harms, and addresses quit-smoking support, which remains part of the package for current smokers. Once eligibility is documented, the scan is ordered at a screening center accredited by the American College of Radiology, and most commercial insurers and Medicare cover it annually for people who meet the USPSTF criteria without out-of-pocket cost under preventive care rules. Results typically arrive within a week or two, and a normal scan, which the Lung-RADS system calls negative or a benign finding, simply returns a person to the annual schedule without further imaging that year. People who start screening are asked to commit to the yearly rhythm, because an isolated scan years apart loses most of the mortality benefit shown in the trials, and clinicians often decline to order screening for someone unlikely or unwilling to complete follow-up.
When to see a doctor
When to see a doctor
Smokers and recent quitters who may meet the pack-year threshold should raise screening with a primary care clinician, who can confirm eligibility, arrange the shared decision-making visit, and order the scan at an accredited center. Symptoms themselves are not the screening pathway: coughing up blood, a cough that persists beyond several weeks, unexplained weight loss, hoarseness, or new shortness of breath warrant prompt evaluation regardless of screening eligibility, since these can indicate established disease. People found to have a nodule under surveillance should attend every scheduled follow-up scan, since missed imaging is among the most common failures in the screening chain.